Catalyst Brief

← Calendar

Readoutin 135d

Innovent Biologics Technology Limited (Shanghai R&D Center) — Febuxostat

Phase 3 primary completion: Tigulixostat (IBI128) vs Febuxostat in Gout.

Date
Apr 2027
Type
Readout
Indication
Gout

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.